Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 8
1964 5
1965 1
1966 2
1967 6
1968 14
1969 13
1970 10
1971 14
1972 27
1973 17
1974 21
1975 22
1976 28
1977 11
1978 19
1979 22
1980 13
1981 16
1982 21
1983 12
1984 26
1985 20
1986 37
1987 56
1988 97
1989 100
1990 144
1991 115
1992 139
1993 120
1994 135
1995 132
1996 146
1997 144
1998 156
1999 175
2000 188
2001 214
2002 229
2003 281
2004 258
2005 232
2006 192
2007 216
2008 167
2009 176
2010 186
2011 190
2012 158
2013 202
2014 231
2015 267
2016 276
2017 250
2018 198
2019 209
2020 195
2021 196
2022 184
2023 188
2024 47

Text availability

Article attribute

Article type

Publication date

Search Results

6,808 results

Results by year

Filters applied: . Clear all
Page 1
A mechanism-based operational definition and classification of hypercholesterolemia.
Civeira F, Arca M, Cenarro A, Hegele RA. Civeira F, et al. J Clin Lipidol. 2022 Nov-Dec;16(6):813-821. doi: 10.1016/j.jacl.2022.09.006. Epub 2022 Sep 30. J Clin Lipidol. 2022. PMID: 36229375 Free article. Review.
In contrast to strong evidence-based clinical recommendations for lipid-lowering treatment, there is no analogous definitive diagnostic definition of hypercholesterolemia and its various subtypes. For many clinicians, guideline indications for hypolipidemic treatment can b …
In contrast to strong evidence-based clinical recommendations for lipid-lowering treatment, there is no analogous definitive diagnostic defi …
Polygenic Hypercholesterolemia and Cardiovascular Disease Risk.
Sharifi M, Futema M, Nair D, Humphries SE. Sharifi M, et al. Curr Cardiol Rep. 2019 Apr 22;21(6):43. doi: 10.1007/s11886-019-1130-z. Curr Cardiol Rep. 2019. PMID: 31011892 Free PMC article. Review.
PURPOSE OF THE REVIEW: Identification of loci and common single-nucleotide polymorphisms (SNPs) that have modest effects on plasma lipids have been used to confirm or refute the causal role of lipid traits in the development of coronary heart disease (CHD), and as tools to identi …
PURPOSE OF THE REVIEW: Identification of loci and common single-nucleotide polymorphisms (SNPs) that have modest effects on plasma lipids ha …
Hypercholesterolemia: The role of PCSK9.
Melendez QM, Krishnaji ST, Wooten CJ, Lopez D. Melendez QM, et al. Arch Biochem Biophys. 2017 Jul 1;625-626:39-53. doi: 10.1016/j.abb.2017.06.001. Epub 2017 Jun 3. Arch Biochem Biophys. 2017. PMID: 28587771 Review.
The effects of PCSK9 on the LDL receptor, the relationship of this convertase with IDOL, and treatments currently available against hypercholesterolemia are also discussed....
The effects of PCSK9 on the LDL receptor, the relationship of this convertase with IDOL, and treatments currently available against hyper …
Epidemiology and management of hyperlipidemia.
Karr S. Karr S. Am J Manag Care. 2017 Jun;23(9 Suppl):S139-S148. Am J Manag Care. 2017. PMID: 28978219 Free article. Review.
Cardiovascular disease (CVD) is the leading cause of death among adults in the United States, and people with hyperlipidemia are at roughly twice the risk of developing CVD as compared to those with normal total cholesterol levels.1 Patients with familial hypercholesterolemia …
Cardiovascular disease (CVD) is the leading cause of death among adults in the United States, and people with hyperlipidemia are at roughly …
The Many Roles of Cholesterol in Sepsis: A Review.
Hofmaenner DA, Kleyman A, Press A, Bauer M, Singer M. Hofmaenner DA, et al. Am J Respir Crit Care Med. 2022 Feb 15;205(4):388-396. doi: 10.1164/rccm.202105-1197TR. Am J Respir Crit Care Med. 2022. PMID: 34715007 Free PMC article. Review.
LDL-cholesterol: The lower the better.
Pedro-Botet J, Pintó X. Pedro-Botet J, et al. Clin Investig Arterioscler. 2019 Dec;31 Suppl 2:16-27. doi: 10.1016/j.arteri.2019.10.003. Epub 2019 Dec 6. Clin Investig Arterioscler. 2019. PMID: 31813618 Review. English, Spanish.
However, due to its cost, its use is restricted to patients with ischaemia or familial hypercholesterolaemia that do not achieve the desired levels with conventional drugs. ...In the next few years, it may be necessary to adjust the intensity of the hypercholesterolaemi …
However, due to its cost, its use is restricted to patients with ischaemia or familial hypercholesterolaemia that do not achieve the …
The Inherited Hypercholesterolemias.
Loh WJ, Watts GF. Loh WJ, et al. Endocrinol Metab Clin North Am. 2022 Sep;51(3):511-537. doi: 10.1016/j.ecl.2022.02.006. Epub 2022 Jul 4. Endocrinol Metab Clin North Am. 2022. PMID: 35963626 Review.
In this review, we discuss familial hypercholesterolemia (FH), FH-mimics (eg, polygenic hypercholesterolemia [PH], FCH, sitosterolemia), and other inherited forms of hypercholesterolemia (eg, hyper-lipoprotein(a) levels [hyper-Lp(a)]). The prevalence, genetic …
In this review, we discuss familial hypercholesterolemia (FH), FH-mimics (eg, polygenic hypercholesterolemia [PH], FCH, sitost …
PCSK9 and Hypercholesterolemia: Therapeutic Approach.
Obradovic M, Zaric B, Sudar-Milovanovic E, Ilincic B, Stokic E, Perovic M, Isenovic ER. Obradovic M, et al. Curr Drug Targets. 2018;19(9):1058-1067. doi: 10.2174/1389450119666171205101401. Curr Drug Targets. 2018. PMID: 29210646 Review.
Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications remain one of the leading causes of mortality and disability in the modern world. A significant contribution to the treatment of hypercho …
Despite the intensive research and progress in modern pharmacotherapy, hypercholesterolemia and related cardiovascular complications …
β-glucans and cholesterol (Review).
Sima P, Vannucci L, Vetvicka V. Sima P, et al. Int J Mol Med. 2018 Apr;41(4):1799-1808. doi: 10.3892/ijmm.2018.3411. Epub 2018 Jan 22. Int J Mol Med. 2018. PMID: 29393350 Free PMC article. Review.
Hypercholesterolemia is one of primary risk factors of cardiovascular disease, together with metabolic syndrome, hypertension and diabetes. ...
Hypercholesterolemia is one of primary risk factors of cardiovascular disease, together with metabolic syndrome, hypertension and dia …
Rosuvastatin.
Carswell CI, Plosker GL, Jarvis B. Carswell CI, et al. Drugs. 2002;62(14):2075-85; discussion 2086-7. doi: 10.2165/00003495-200262140-00008. Drugs. 2002. PMID: 12269853 Review.
In well designed trials of between 6 and 52 weeks' duration, rosuvastatin was superior to atorvastatin, simvastatin and pravastatin in improving the lipid profile of patients with hypercholesterolaemia. In a 1-year dose-titration study, rosuvastatin 13.4mg daily (mean dose …
In well designed trials of between 6 and 52 weeks' duration, rosuvastatin was superior to atorvastatin, simvastatin and pravastatin in impro …
6,808 results